{
    "metoclopramide": {
        "stop": [
            {
                "Metoclopramide": "With Parkinsonism (risk of exacerbating symptoms). After maximum treatment time of 5 days."
            }
        ],
        "start": [],
        "score": 0
    },
    "domperidone": {
        "stop": [
            {
                "Domperidone": "For treatment other than nausea and vomiting. After maximum treatment time of one week.\nIn patients with serious underlying heart conditions. If receiving other medications known to prolong QT interval or potent. CYP3A4 inhibitors."
            }
        ],
        "start": [],
        "score": 0
    },
    "omeprazole": {
        "stop": [
            {
                "Proton pump inhibitor": "For uncomplicated peptic ulcer disease at full therapeutic dosage after 1-2 months (if healed, offer low dose maintenance treatment, possibly on an \u2018as required\u2019 basis - review at least annually)"
            }
        ],
        "start": [
            {
                "Proton pump inhibitor": "At full dose, long term (initially 8 weeks, if symptoms resolve consider full dose maintenance, review annually) with severe grade oesophagitis or oesophageal stricture requiring dilation. For patients on medication with risk of gastric bleeding eg. antiplatelets, SSRIs, venlafaxine, corticosteroids, NSAIDs (particularly if in combination where unavoidable)"
            }
        ],
        "score": 1
    },
    "lansoprazole": {
        "stop": [
            {
                "Proton pump inhibitor": "For uncomplicated peptic ulcer disease at full therapeutic dosage after 1-2 months (if healed, offer low dose maintenance treatment, possibly on an \u2018as required\u2019 basis - review at least annually)"
            }
        ],
        "start": [
            {
                "Proton pump inhibitor": "At full dose, long term (initially 8 weeks, if symptoms resolve consider full dose maintenance, review annually) with severe grade oesophagitis or oesophageal stricture requiring dilation. For patients on medication with risk of gastric bleeding eg. antiplatelets, SSRIs, venlafaxine, corticosteroids, NSAIDs (particularly if in combination where unavoidable)"
            }
        ],
        "score": 1
    },
    "esomeprazole": {
        "stop": [
            {
                "Proton pump inhibitor": "For uncomplicated peptic ulcer disease at full therapeutic dosage after 1-2 months (if healed, offer low dose maintenance treatment, possibly on an \u2018as required\u2019 basis - review at least annually)"
            }
        ],
        "start": [
            {
                "Proton pump inhibitor": "At full dose, long term (initially 8 weeks, if symptoms resolve consider full dose maintenance, review annually) with severe grade oesophagitis or oesophageal stricture requiring dilation. For patients on medication with risk of gastric bleeding eg. antiplatelets, SSRIs, venlafaxine, corticosteroids, NSAIDs (particularly if in combination where unavoidable)"
            }
        ],
        "score": 0
    },
    "famotidine": {
        "stop": [
            {
                "Proton pump inhibitor": "For uncomplicated peptic ulcer disease at full therapeutic dosage after 1-2 months (if healed, offer low dose maintenance treatment, possibly on an \u2018as required\u2019 basis - review at least annually)"
            }
        ],
        "start": [],
        "score": 0
    },
    "loperamide hydrochloride": {
        "stop": [
            {
                "Antimotility drugs": "Should be AVOIDED if there is blood and mucus in stools or high fever during severe infective gastroenteritis."
            }
        ],
        "start": [],
        "score": 0
    },
    "co-phenotrope": {
        "stop": [
            {
                "Antimotility drugs": "Should be AVOIDED if there is blood and mucus in stools or high fever during severe infective gastroenteritis."
            }
        ],
        "start": [],
        "score": 0
    },
    "loperamide hydrochloride and simeticone": {
        "stop": [
            {
                "Antimotility drugs": "Should be AVOIDED if there is blood and mucus in stools or high fever during severe infective gastroenteritis."
            }
        ],
        "start": [],
        "score": 0
    },
    "pantoprazole": {
        "stop": [],
        "start": [
            {
                "Proton pump inhibitor": "At full dose, long term (initially 8 weeks, if symptoms resolve consider full dose maintenance, review annually) with severe grade oesophagitis or oesophageal stricture requiring dilation. For patients on medication with risk of gastric bleeding eg. antiplatelets, SSRIs, venlafaxine, corticosteroids, NSAIDs (particularly if in combination where unavoidable)"
            }
        ],
        "score": 1
    },
    "rabeprazole sodium": {
        "stop": [],
        "start": [
            {
                "Proton pump inhibitor": "At full dose, long term (initially 8 weeks, if symptoms resolve consider full dose maintenance, review annually) with severe grade oesophagitis or oesophageal stricture requiring dilation. For patients on medication with risk of gastric bleeding eg. antiplatelets, SSRIs, venlafaxine, corticosteroids, NSAIDs (particularly if in combination where unavoidable)"
            }
        ],
        "score": 0
    },
    "bran": {
        "stop": [],
        "start": [
            {
                "Fibre supplements ( e.g. bran, isphagula, methylcellulose, sterculia)": "for diverticulosis with a history of constipation."
            }
        ],
        "score": 0
    },
    "isphagula": {
        "stop": [],
        "start": [
            {
                "Fibre supplements ( e.g. bran, isphagula, methylcellulose, sterculia)": "for diverticulosis with a history of constipation."
            }
        ],
        "score": 0
    },
    "methylcellulose": {
        "stop": [],
        "start": [
            {
                "Fibre supplements ( e.g. bran, isphagula, methylcellulose, sterculia)": "for diverticulosis with a history of constipation."
            }
        ],
        "score": 0
    },
    "sterculia": {
        "stop": [],
        "start": [
            {
                "Fibre supplements ( e.g. bran, isphagula, methylcellulose, sterculia)": "for diverticulosis with a history of constipation."
            }
        ],
        "score": 0
    },
    "digoxin": {
        "stop": [
            {
                "Digoxin": "For heart failure with normal systolic ventricular function (no clear evidence of benefit).\nFor left systolic ventricular dysfunction, where key interventions have not previously been tried (see START). At a long-term dose greater than 125 micrograms/day if eGFR less than 30 ml/min/1.73m2 (risk of toxicity if digoxin plasma levels not measured as eGFR may not be an accurate indicator of clearance)."
            }
        ],
        "start": [],
        "score": 1
    },
    "bendroflumethiazide": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "chlorothiazide": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "chlortalidone": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 1
    },
    "cyclopenthiazide": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "hydrochlorothiazide": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "indapamide": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "metolazone": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "polythiazide": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "xipamide": {
        "stop": [
            {
                "Thiazide diuretic": "With current significant hypokalaemia (i.e. serum K+ less than 3.0 mmol/L), hyponatraemia (i.e. serum Na+ less than 130 mmol/L) hypercalcaemia (i.e. corrected serum calcium greater than 2.65 mmol/L) or with recent/ concurrent gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "bumetanide": {
        "stop": [
            {
                "Loop diuretic": "As treatment for hypertension (safer, more effective alternatives available). For dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and/ or compression hosiery usually more appropriate)"
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "furosemide": {
        "stop": [
            {
                "Loop diuretic": "As treatment for hypertension (safer, more effective alternatives available). For dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and/ or compression hosiery usually more appropriate)"
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "torasemide": {
        "stop": [
            {
                "Loop diuretic": "As treatment for hypertension (safer, more effective alternatives available). For dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and/ or compression hosiery usually more appropriate)"
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "spironolactone": {
        "stop": [
            {
                "Aldosterone antagonists": "AIIRAs particularly if co-prescribed with potassium-conserving drugs (e.g. ACEIs, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous hyperkalaemia i.e. greater than 6.0 mmol/L \u2013 serum K should be monitored regularly, i.e. at least every 6 months)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "eplerenone": {
        "stop": [
            {
                "Aldosterone antagonists": "AIIRAs particularly if co-prescribed with potassium-conserving drugs (e.g. ACEIs, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous hyperkalaemia i.e. greater than 6.0 mmol/L \u2013 serum K should be monitored regularly, i.e. at least every 6 months)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "finerenone": {
        "stop": [
            {
                "Aldosterone antagonists": "AIIRAs particularly if co-prescribed with potassium-conserving drugs (e.g. ACEIs, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous hyperkalaemia i.e. greater than 6.0 mmol/L \u2013 serum K should be monitored regularly, i.e. at least every 6 months)."
            },
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "verapamil": {
        "stop": [
            {
                "Verapamil, diltiazem": "With heart failure (may worsen heart failure)"
            }
        ],
        "start": [],
        "score": 0
    },
    "diltiazem": {
        "stop": [
            {
                "Verapamil, diltiazem": "With heart failure (may worsen heart failure)"
            }
        ],
        "start": [],
        "score": 0
    },
    "nicorandil": {
        "stop": [
            {
                "Nicorandil": "If ulceration of the gastro-intestinal tract, skin or mucosa (including eyes) occurs; consider alternative treatment or specialist advice if angina worsens (ulcers caused by Nicorandil do not respond to conventional treatment)."
            }
        ],
        "start": [],
        "score": 0
    },
    "captopril": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 1
    },
    "cilazapril": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "co-zidocapt (hydrochlorothiazide/captopril)": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "enalapril maleate": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "enalapril maleate with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "fosinopril sodium": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "imidapril hydrochloride": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "lisinopril": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "lisinopril with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "moexipril hydrochloride": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "perindopril arginine": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "perindopril arginine with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "perindopril erbumine": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "perindopril erbumine with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "perindopril tosilate": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "perindopril tosilate/indapamide": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "perindopril with calcium channel blocker": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "quinapril hydrochloride": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "quinapril hydrochloride with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "ramipril": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "ramipril with calcium channel blocker": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "trandolapril": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 1
    },
    "trandolapril with calcium channel blocker": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            },
            {
                "Angiotensin-converting enzyme inhibitors": "With a known history of persistent bradycardia (below 60 beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors": "With systolic heart failure and/or documented coronary artery disease."
            },
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "azilsartan medoxomil": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "candesartan cilexetil": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "eprosartan": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "irbesartan": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "irbesartan with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "losartan potassium": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "losartan potassium with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "olmesartan medoxomil": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "olmesartan medoxomil/amlodipine": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "olmesartan medoxomil/amlodipine/hydrochlorothiazide": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "olmesartan medoxomil/hydrochlorothiazide": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "sacubitril/valsartan": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "telmisartan": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "telmisartan with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "valsartan": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "valsartan with diuretic": {
        "stop": [
            {
                "Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonist": "In patients with hyperkalaemia. In combination with each other (limited evidence of benefit) \u2013 unless under specialist review and recommendation."
            }
        ],
        "start": [
            {
                "Angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonist  (if intolerant of ACEI)": "In diabetes with evidence of renal disease i.e. dipstick proteinuria or microalbuminuria (greater than 30 mg/24 hours) with or without serum biochemical renal impairment."
            }
        ],
        "score": 0
    },
    "methyldopa": {
        "stop": [
            {
                "Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine)": "Unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives (centrally-active antihypertensives are generally less well tolerated by older people than younger people)."
            }
        ],
        "start": [],
        "score": 0
    },
    "clonidine": {
        "stop": [
            {
                "Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine)": "Unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives (centrally-active antihypertensives are generally less well tolerated by older people than younger people)."
            }
        ],
        "start": [],
        "score": 0
    },
    "moxonidine": {
        "stop": [
            {
                "Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine)": "Unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives (centrally-active antihypertensives are generally less well tolerated by older people than younger people)."
            }
        ],
        "start": [],
        "score": 0
    },
    "amiodarone": {
        "stop": [
            {
                "Amiodarone": "As first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem), following review and recommendation by specialist team."
            }
        ],
        "start": [],
        "score": 0
    },
    "amlodipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "diltiazem hydrochloride": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "felodipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "isradipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "lacidipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "lercanidipine hydrochloride": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "nicardipine hydrochloride": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "nifedipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "nimodipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "nisoldipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "trimetazidine hydrochloride": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "valsartan/amlodipine": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "verapamil hydrochloride": {
        "stop": [],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            }
        ],
        "score": 0
    },
    "acebutolol hydrochloride": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "atenolol": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "atenolol with calcium channel blocker": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "atenolol with diuretic": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "bisoprolol fumarate": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "bisoprolol fumarate/aspirin": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "carvedilol": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "celiprolol hydrochloride": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "co-prenozide (oxprenolol hydrochloride/cyclopenthiazide)": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "co-tenidone (atenolol/chlortalidone)": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "labetalol hydrochloride": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "metoprolol tartrate": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "metoprolol tartrate with diuretic": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "nadolol": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "nebivolol": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "oxprenolol hydrochloride": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "pindolol": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "pindolol with diuretic": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "propranolol hydrochloride": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "propranolol hydrochloride with diuretic": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "sotalol hydrochloride": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "timolol": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            },
            {
                "Topical prostaglandin, prostamide or beta-blocker": "For primary open-angle glaucoma."
            }
        ],
        "score": 0
    },
    "timolol with diuretic": {
        "stop": [
            {
                "Non-selective beta-blocker": "With a recent history of bradycardia, heart block or uncontrolled heart failure; or asthma requiring treatment (risk of increased bronchospasm) (whether oral or topical for glaucoma)."
            }
        ],
        "start": [
            {
                "Beta-blocker or Calcium channel blocker": "For stable angina."
            },
            {
                "Appropriate beta-blocker": "With stable systolic heart failure."
            }
        ],
        "score": 0
    },
    "atorvastatin": {
        "stop": [],
        "start": [
            {
                "Statin": "Discussion with patients with known coronary heart disease, QRISK greater than 10%, diabetes type 1 or 2, or CKD with eGFR less than 60 min/1.73m2, consider for 85 years or over . Use Atorvastatin first line."
            }
        ],
        "score": 0
    },
    "fluvastin": {
        "stop": [],
        "start": [
            {
                "Statin": "Discussion with patients with known coronary heart disease, QRISK greater than 10%, diabetes type 1 or 2, or CKD with eGFR less than 60 min/1.73m2, consider for 85 years or over . Use Atorvastatin first line."
            }
        ],
        "score": 0
    },
    "lovastatin": {
        "stop": [],
        "start": [
            {
                "Statin": "Discussion with patients with known coronary heart disease, QRISK greater than 10%, diabetes type 1 or 2, or CKD with eGFR less than 60 min/1.73m2, consider for 85 years or over . Use Atorvastatin first line."
            }
        ],
        "score": 0
    },
    "pitavastatin": {
        "stop": [],
        "start": [
            {
                "Statin": "Discussion with patients with known coronary heart disease, QRISK greater than 10%, diabetes type 1 or 2, or CKD with eGFR less than 60 min/1.73m2, consider for 85 years or over . Use Atorvastatin first line."
            }
        ],
        "score": 0
    },
    "pravastatin": {
        "stop": [],
        "start": [
            {
                "Statin": "Discussion with patients with known coronary heart disease, QRISK greater than 10%, diabetes type 1 or 2, or CKD with eGFR less than 60 min/1.73m2, consider for 85 years or over . Use Atorvastatin first line."
            }
        ],
        "score": 0
    },
    "rosuvastatin": {
        "stop": [],
        "start": [
            {
                "Statin": "Discussion with patients with known coronary heart disease, QRISK greater than 10%, diabetes type 1 or 2, or CKD with eGFR less than 60 min/1.73m2, consider for 85 years or over . Use Atorvastatin first line."
            }
        ],
        "score": 0
    },
    "simvastatin": {
        "stop": [],
        "start": [
            {
                "Statin": "Discussion with patients with known coronary heart disease, QRISK greater than 10%, diabetes type 1 or 2, or CKD with eGFR less than 60 min/1.73m2, consider for 85 years or over . Use Atorvastatin first line."
            }
        ],
        "score": 0
    },
    "aspirin": {
        "stop": [
            {
                "Aspirin": "Long-term aspirin at doses greater than 160 mg per day (increased risk of bleeding, no evidence for increased efficacy). With a past history of peptic ulcer disease without concomitant PPI (risk of recurrent peptic ulcer). In combination with warfarin or NOACs in patients with chronic atrial fibrillation (no added benefit from aspirin). As monotherapy for stroke prevention in atrial fibrillation."
            },
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            },
            {
                "Aspirin PLUS clopidogrel": "As secondary stroke prevention, unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis (no evidence of added benefit over clopidogrel monotherapy)."
            },
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            },
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            }
        ],
        "start": [
            {
                "Antiplatelet therapy (one of aspirin, clopidogrel, prasugrel or ticagrelor)": "With a documented history of coronary, cerebral or peripheral vascular disease."
            }
        ],
        "score": 0
    },
    "clopidogrel": {
        "stop": [
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            },
            {
                "Aspirin PLUS clopidogrel": "As secondary stroke prevention, unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis (no evidence of added benefit over clopidogrel monotherapy)."
            },
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            }
        ],
        "start": [
            {
                "Antiplatelet therapy (one of aspirin, clopidogrel, prasugrel or ticagrelor)": "With a documented history of coronary, cerebral or peripheral vascular disease."
            }
        ],
        "score": 0
    },
    "dipyramidole": {
        "stop": [
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            }
        ],
        "start": [],
        "score": 0
    },
    "warfarin": {
        "stop": [
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            },
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            },
            {
                "Warfarin or NOACs": "For first deep vein thrombosis without continuing provoking risk factors (e.g.thrombophilia) for longer than 6 months (no proven added benefit). For first pulmonary embolus without continuing provoking risk factors (e.g.thrombophilia) for longer than 12 months (no proven added benefit)."
            },
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            }
        ],
        "start": [
            {
                "Anticoagulation (apixaban, edoxaban, warfarin, dabigatran, rivaroxaban)": "For atrial fibrillation, using the CHA2DS2-VASc and HAS- BLED score and discuss the risk and benefit with the patient. Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above (1 or above for males), taking bleeding risk into account. Anticoagulation can be either Warfarin or a NOAC."
            }
        ],
        "score": 0
    },
    "apixaban": {
        "stop": [
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            },
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            },
            {
                "Warfarin or NOACs": "For first deep vein thrombosis without continuing provoking risk factors (e.g.thrombophilia) for longer than 6 months (no proven added benefit). For first pulmonary embolus without continuing provoking risk factors (e.g.thrombophilia) for longer than 12 months (no proven added benefit)."
            },
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "Factor Xa inhibitors": "If eGFR less than 15 ml/min/1.73m2 (risk of bleeding)."
            }
        ],
        "start": [
            {
                "Anticoagulation (apixaban, edoxaban, warfarin, dabigatran, rivaroxaban)": "For atrial fibrillation, using the CHA2DS2-VASc and HAS- BLED score and discuss the risk and benefit with the patient. Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above (1 or above for males), taking bleeding risk into account. Anticoagulation can be either Warfarin or a NOAC."
            }
        ],
        "score": 0
    },
    "dabigatran": {
        "stop": [
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            },
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            },
            {
                "Warfarin or NOACs": "For first deep vein thrombosis without continuing provoking risk factors (e.g.thrombophilia) for longer than 6 months (no proven added benefit). For first pulmonary embolus without continuing provoking risk factors (e.g.thrombophilia) for longer than 12 months (no proven added benefit)."
            },
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "Direct thrombin inhibitors": "If eGFR less than 30 ml/min/1.73m2 (risk of bleeding)."
            }
        ],
        "start": [
            {
                "Anticoagulation (apixaban, edoxaban, warfarin, dabigatran, rivaroxaban)": "For atrial fibrillation, using the CHA2DS2-VASc and HAS- BLED score and discuss the risk and benefit with the patient. Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above (1 or above for males), taking bleeding risk into account. Anticoagulation can be either Warfarin or a NOAC."
            }
        ],
        "score": 0
    },
    "rivaroxaban": {
        "stop": [
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            },
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            },
            {
                "Warfarin or NOACs": "For first deep vein thrombosis without continuing provoking risk factors (e.g.thrombophilia) for longer than 6 months (no proven added benefit). For first pulmonary embolus without continuing provoking risk factors (e.g.thrombophilia) for longer than 12 months (no proven added benefit)."
            },
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "Factor Xa inhibitors": "If eGFR less than 15 ml/min/1.73m2 (risk of bleeding)."
            }
        ],
        "start": [
            {
                "Anticoagulation (apixaban, edoxaban, warfarin, dabigatran, rivaroxaban)": "For atrial fibrillation, using the CHA2DS2-VASc and HAS- BLED score and discuss the risk and benefit with the patient. Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above (1 or above for males), taking bleeding risk into account. Anticoagulation can be either Warfarin or a NOAC."
            }
        ],
        "score": 0
    },
    "edoxaban": {
        "stop": [
            {
                "Aspirin, clopidogrel, dipyridamole, warfarin or NOACs": "With concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
            },
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            },
            {
                "Warfarin or NOACs": "For first deep vein thrombosis without continuing provoking risk factors (e.g.thrombophilia) for longer than 6 months (no proven added benefit). For first pulmonary embolus without continuing provoking risk factors (e.g.thrombophilia) for longer than 12 months (no proven added benefit)."
            },
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "Factor Xa inhibitors": "If eGFR less than 15 ml/min/1.73m2 (risk of bleeding)."
            }
        ],
        "start": [
            {
                "Anticoagulation (apixaban, edoxaban, warfarin, dabigatran, rivaroxaban)": "For atrial fibrillation, using the CHA2DS2-VASc and HAS- BLED score and discuss the risk and benefit with the patient. Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above (1 or above for males), taking bleeding risk into account. Anticoagulation can be either Warfarin or a NOAC."
            }
        ],
        "score": 0
    },
    "dipyridamole": {
        "stop": [
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            }
        ],
        "start": [],
        "score": 0
    },
    "dipyridamole and aspirin": {
        "stop": [
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            }
        ],
        "start": [],
        "score": 0
    },
    "eptifibatide": {
        "stop": [
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            }
        ],
        "start": [],
        "score": 0
    },
    "prasugrel": {
        "stop": [
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            }
        ],
        "start": [
            {
                "Antiplatelet therapy (one of aspirin, clopidogrel, prasugrel or ticagrelor)": "With a documented history of coronary, cerebral or peripheral vascular disease."
            }
        ],
        "score": 0
    },
    "ticagrelor": {
        "stop": [
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            }
        ],
        "start": [
            {
                "Antiplatelet therapy (one of aspirin, clopidogrel, prasugrel or ticagrelor)": "With a documented history of coronary, cerebral or peripheral vascular disease."
            }
        ],
        "score": 0
    },
    "ticlopidine hydrochloride": {
        "stop": [
            {
                "Antiplatelet agents with warfarin or NOACs": "In patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy)."
            }
        ],
        "start": [],
        "score": 0
    },
    "ibuprofen": {
        "stop": [
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            },
            {
                "Diclofenac, COX-2 selective / specific agents or Ibuprofen dose greater than 1200 mg per day": "With concurrent cardiovascular disease (increased risk of thrombotic events)."
            }
        ],
        "start": [],
        "score": 0
    },
    "naproxen": {
        "stop": [
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "diclofenac": {
        "stop": [
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "Diclofenac, COX-2 selective / specific agents or Ibuprofen dose greater than 1200 mg per day": "With concurrent cardiovascular disease (increased risk of thrombotic events)."
            }
        ],
        "start": [],
        "score": 0
    },
    "celecoxib": {
        "stop": [
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 1
    },
    "mefenamic acid": {
        "stop": [
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "etoricoxib": {
        "stop": [
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            },
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 1
    },
    "indomethacin": {
        "stop": [
            {
                "Non steroidal anti-inflammatories PLUS warfarin or NOACs": "In combination (risk of major gastro-intestinal bleeding)."
            }
        ],
        "start": [],
        "score": 0
    },
    "argatroban": {
        "stop": [
            {
                "Direct thrombin inhibitors": "If eGFR less than 30 ml/min/1.73m2 (risk of bleeding)."
            }
        ],
        "start": [],
        "score": 0
    },
    "bivalirudin": {
        "stop": [
            {
                "Direct thrombin inhibitors": "If eGFR less than 30 ml/min/1.73m2 (risk of bleeding)."
            }
        ],
        "start": [],
        "score": 0
    },
    "aclidinium brom/formoterol": {
        "stop": [
            {
                "Anti-muscarinic bronchodilators": "With a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "aclidinium bromide": {
        "stop": [
            {
                "Anti-muscarinic bronchodilators": "With a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "glycopyrronium bromide": {
        "stop": [
            {
                "Anti-muscarinic bronchodilators": "With a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "ipratropium bromide": {
        "stop": [
            {
                "Anti-muscarinic bronchodilators": "With a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "oxitropium bromide": {
        "stop": [
            {
                "Anti-muscarinic bronchodilators": "With a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "tiotropium bromide": {
        "stop": [
            {
                "Anti-muscarinic bronchodilators": "With a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "umeclidinium bromide": {
        "stop": [
            {
                "Anti-muscarinic bronchodilators": "With a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "theophylline": {
        "stop": [
            {
                "Theophylline": "As monotherapy for Asthma or COPD (safer, more effective alternative; risk of adverse effects due to narrow therapeutic index)."
            }
        ],
        "start": [],
        "score": 1
    },
    "prednisone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 0
    },
    "prednisolone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 1
    },
    "methylprednisolone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 1
    },
    "beclomethasone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 0
    },
    "betamethasone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 0
    },
    "dexamethasone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 1
    },
    "hydrocortisone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 1
    },
    "triamcinolone": {
        "stop": [
            {
                "Systemic corticosteroids": "Instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side- effects of systemic corticosteroids and effective inhaled therapies are available)."
            },
            {
                "Long-term corticosteroids": "As monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects)(longer than 3 months)."
            },
            {
                "Corticosteroids": "For osteoarthritis (risk of systemic corticosteroid side-effects)(other than periodic intra-articular injections for mono-articular pain) ."
            }
        ],
        "start": [],
        "score": 1
    },
    "beclometasone dipropionate": {
        "stop": [],
        "start": [
            {
                "Regular inhaled corticosteroid": "For moderate-severe asthma or COPD (where FEV1 less than 50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids). Give a steroid warning card for high doses."
            }
        ],
        "score": 0
    },
    "budesonide": {
        "stop": [],
        "start": [
            {
                "Regular inhaled corticosteroid": "For moderate-severe asthma or COPD (where FEV1 less than 50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids). Give a steroid warning card for high doses."
            }
        ],
        "score": 0
    },
    "ciclesonide": {
        "stop": [],
        "start": [
            {
                "Regular inhaled corticosteroid": "For moderate-severe asthma or COPD (where FEV1 less than 50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids). Give a steroid warning card for high doses."
            }
        ],
        "score": 0
    },
    "fluticasone propionate": {
        "stop": [],
        "start": [
            {
                "Regular inhaled corticosteroid": "For moderate-severe asthma or COPD (where FEV1 less than 50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids). Give a steroid warning card for high doses."
            }
        ],
        "score": 0
    },
    "mometasone furoate": {
        "stop": [],
        "start": [
            {
                "Regular inhaled corticosteroid": "For moderate-severe asthma or COPD (where FEV1 less than 50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids). Give a steroid warning card for high doses."
            }
        ],
        "score": 0
    },
    "amitriptyline hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "amoxapine": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 3
    },
    "clomipramine hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "dosulepin hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "doxepin": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 3
    },
    "imipramine hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "lofepramine hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "maprotiline hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "mianserin hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "nortriptyline": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 3
    },
    "trazodone hydrochloride": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "trimipramine maleate": {
        "stop": [
            {
                "Tricyclic antidepressants (TCA) (particularly Dosulepin)": "With dementia (risk of worsening cognitive impairment). With glaucoma (likely to exacerbate glaucoma). With cardiac conductive abnormalities (pro-arrhythmic effects). With constipation or medication likely to exacerbate constipation, following review (likely to worsen constipation).\nWith prostatism or prior history of urinary retention (risk of urinary retention)."
            }
        ],
        "start": [],
        "score": 0
    },
    "diazepam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 1
    },
    "alprazolam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 1
    },
    "chlordiazepoxide hydrochloride": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "clobazam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "lorazepam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 1
    },
    "oxazepam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 1
    },
    "chloral hydrate": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "clomethiazole": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "clomethiazole edisilate": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "cloral betaine": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "flurazepam hydrochloride": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "loprazolam mesilate": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "lormetazepam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "melatonin": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "midazolam maleate": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "nitrazepam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 1
    },
    "other hypnotic preparations": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "sodium oxybate": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "temazepam": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "triclofos sodium": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "zaleplon": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "zolpidem tartrate": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "zopiclone": {
        "stop": [
            {
                "Benzodiazepines or hypnotics": "With acute or chronic respiratory failure i.e. pO2 less than 8.0 kPa and/ or pCO2 greater than 6.5 kPa (risk of exacerbation of respiratory failure). If fallen in past 3 months. For longer than 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines/ hypnotics should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a withdrawal syndrome if stopped abruptly)."
            }
        ],
        "start": [],
        "score": 0
    },
    "misulpride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "aripiprazole": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 1
    },
    "benperidol": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "cariprazine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "chlorpromazine hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            },
            {
                "Phenothiazines": "In patients with epilepsy (may lower seizure threshold). As first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people), with the exception of prochloprerazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
            }
        ],
        "start": [],
        "score": 0
    },
    "chlorprothixene": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 3
    },
    "clozapine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 3
    },
    "flupentixol hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "fluphenazine hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "haloperidol": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 1
    },
    "levomepromazine hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "levomepromazine maleate": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "loxapine succinate": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "lurasidone": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "melperone hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "olanzapine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 3
    },
    "paliperidone": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "pericyazine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            },
            {
                "Phenothiazines": "In patients with epilepsy (may lower seizure threshold). As first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people), with the exception of prochloprerazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
            }
        ],
        "start": [],
        "score": 3
    },
    "perphenazine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 2
    },
    "pimozide": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 2
    },
    "promazine hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            },
            {
                "Phenothiazines": "In patients with epilepsy (may lower seizure threshold). As first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people), with the exception of prochloprerazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
            }
        ],
        "start": [],
        "score": 0
    },
    "quetiapine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 3
    },
    "risperidone": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 1
    },
    "sulpiride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "thioridazine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 3
    },
    "trifluoperazine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            },
            {
                "Phenothiazines": "In patients with epilepsy (may lower seizure threshold). As first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people), with the exception of prochloprerazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
            }
        ],
        "start": [],
        "score": 2
    },
    "ziprasidone hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "zotepine": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "zuclopenthixol acetate": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "zuclopenthixol hydrochloride": {
        "stop": [
            {
                "Antipsychotics": "Long-term (i.e. beyond 1 month) as hypnotics (risk of confusion, hypotension, extra-pyramidal side effects, falls). Long-term ( beyond 1 month) in those with Parkinsonism or Lewy Body Disease (likely to worsen extra-pyramidal symptoms). If fallen in past 3 months (may cause gait dyspraxia, Parkinsonism). With moderate \u2013marked antimuscarinic/ anticholinergic effects. (chlorpromazine, clozapine, flupenthixol, flupenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary retention). In patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). As hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, extra-pyramidal side \u2013effects, falls)."
            }
        ],
        "start": [],
        "score": 0
    },
    "amantadine hydrochloride": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "apomorphine hydrochloride": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "apomorphine hydrochloride hemihydrate": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "cabergoline": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "carbidopa": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "co-beneldopa (benserazide/levodopa)": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "co-careldopa (carbidopa/levodopa)": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "entacapone": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 1
    },
    "levodopa": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 1
    },
    "levodopa/carbidopa/entacapone": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "memantine hydrochloride": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "opicapone": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "pergolide mesilate": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "pramipexole": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            },
            {
                "Dopamine agonist (ropinirole or pramipexole or rotigotine)": "For moderate-severe Restless Legs Syndrome, once iron deficiency and severe renal failure have been excluded and in conjunction with lifestyle measures."
            }
        ],
        "score": 1
    },
    "rasagiline mesilate": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "ropinirole hydrochloride": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "rotigotine": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            },
            {
                "Dopamine agonist (ropinirole or pramipexole or rotigotine)": "For moderate-severe Restless Legs Syndrome, once iron deficiency and severe renal failure have been excluded and in conjunction with lifestyle measures."
            }
        ],
        "score": 1
    },
    "safinamide": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "selegiline hydrochloride": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "tolcapone": {
        "stop": [
            {
                "Levodopa or dopamine agonists": "For benign essential tremor (no evidence of efficacy)."
            }
        ],
        "start": [
            {
                "Levodopa or dopamine agonist": "In idiopathic Parkinson\u2019s disease with definite functional impairment and resultant disability."
            }
        ],
        "score": 0
    },
    "fluphenazine decanoate": {
        "stop": [
            {
                "Phenothiazines": "In patients with epilepsy (may lower seizure threshold). As first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people), with the exception of prochloprerazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
            }
        ],
        "start": [],
        "score": 0
    },
    "levomepromazine": {
        "stop": [
            {
                "Phenothiazines": "In patients with epilepsy (may lower seizure threshold). As first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people), with the exception of prochloprerazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
            }
        ],
        "start": [],
        "score": 3
    },
    "prochlorperazine": {
        "stop": [
            {
                "Phenothiazines": "In patients with epilepsy (may lower seizure threshold). As first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people), with the exception of prochloprerazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
            }
        ],
        "start": [],
        "score": 1
    },
    "citalopram hydrobromide": {
        "stop": [
            {
                "Selective serotonin re-uptake inhibitors": "With a history of clinically significant hyponatraemia (below 130 mmol/l within the previous 2 months)."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Selective serotonin re-uptake inhibitors": "(or SNRI if SSRI is contra-indicated). For persistent severe anxiety that interferes with independent functioning, or for social anxiety disorder where patient declines cognitive behavioural therapy."
            }
        ],
        "score": 0
    },
    "duloxetine hydrochloride": {
        "stop": [
            {
                "Selective serotonin re-uptake inhibitors": "With a history of clinically significant hyponatraemia (below 130 mmol/l within the previous 2 months)."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Selective serotonin re-uptake inhibitors": "(or SNRI if SSRI is contra-indicated). For persistent severe anxiety that interferes with independent functioning, or for social anxiety disorder where patient declines cognitive behavioural therapy."
            }
        ],
        "score": 0
    },
    "escitalopram": {
        "stop": [
            {
                "Selective serotonin re-uptake inhibitors": "With a history of clinically significant hyponatraemia (below 130 mmol/l within the previous 2 months)."
            },
            {
                "Citalopram and Escitalopram": "With QT-interval prolongation or with concomitant drugs that cause prolonged QT-interval."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Selective serotonin re-uptake inhibitors": "(or SNRI if SSRI is contra-indicated). For persistent severe anxiety that interferes with independent functioning, or for social anxiety disorder where patient declines cognitive behavioural therapy."
            }
        ],
        "score": 1
    },
    "fluoxetine hydrochloride": {
        "stop": [
            {
                "Selective serotonin re-uptake inhibitors": "With a history of clinically significant hyponatraemia (below 130 mmol/l within the previous 2 months)."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Selective serotonin re-uptake inhibitors": "(or SNRI if SSRI is contra-indicated). For persistent severe anxiety that interferes with independent functioning, or for social anxiety disorder where patient declines cognitive behavioural therapy."
            }
        ],
        "score": 0
    },
    "fluvoxamine maleate": {
        "stop": [
            {
                "Selective serotonin re-uptake inhibitors": "With a history of clinically significant hyponatraemia (below 130 mmol/l within the previous 2 months)."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Selective serotonin re-uptake inhibitors": "(or SNRI if SSRI is contra-indicated). For persistent severe anxiety that interferes with independent functioning, or for social anxiety disorder where patient declines cognitive behavioural therapy."
            }
        ],
        "score": 0
    },
    "paroxetine hydrochloride": {
        "stop": [
            {
                "Selective serotonin re-uptake inhibitors": "With a history of clinically significant hyponatraemia (below 130 mmol/l within the previous 2 months)."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Selective serotonin re-uptake inhibitors": "(or SNRI if SSRI is contra-indicated). For persistent severe anxiety that interferes with independent functioning, or for social anxiety disorder where patient declines cognitive behavioural therapy."
            }
        ],
        "score": 0
    },
    "sertraline hydrochloride": {
        "stop": [
            {
                "Selective serotonin re-uptake inhibitors": "With a history of clinically significant hyponatraemia (below 130 mmol/l within the previous 2 months)."
            }
        ],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            },
            {
                "Selective serotonin re-uptake inhibitors": "(or SNRI if SSRI is contra-indicated). For persistent severe anxiety that interferes with independent functioning, or for social anxiety disorder where patient declines cognitive behavioural therapy."
            }
        ],
        "score": 0
    },
    "citalopram": {
        "stop": [
            {
                "Citalopram and Escitalopram": "With QT-interval prolongation or with concomitant drugs that cause prolonged QT-interval."
            }
        ],
        "start": [],
        "score": 1
    },
    "chlorphenamine": {
        "stop": [
            {
                "First generation antihistamines ": "If prolonged use (longer than 1 week) i.e. chlorphenamine, cyclizine, promethazine (risk of sedation and anti-cholinergic side effects)."
            }
        ],
        "start": [],
        "score": 3
    },
    "cyclizine": {
        "stop": [
            {
                "First generation antihistamines ": "If prolonged use (longer than 1 week) i.e. chlorphenamine, cyclizine, promethazine (risk of sedation and anti-cholinergic side effects)."
            }
        ],
        "start": [],
        "score": 3
    },
    "promethazine": {
        "stop": [
            {
                "First generation antihistamines ": "If prolonged use (longer than 1 week) i.e. chlorphenamine, cyclizine, promethazine (risk of sedation and anti-cholinergic side effects)."
            }
        ],
        "start": [],
        "score": 3
    },
    "alimemazine tartrate": {
        "stop": [
            {
                "First generation antihistamines ": "If prolonged use (longer than 1 week) i.e. chlorphenamine, cyclizine, promethazine (risk of sedation and anti-cholinergic side effects)."
            }
        ],
        "start": [],
        "score": 0
    },
    "alfentanil": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "aspirin with codeine": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "bupivacaine with fentanyl": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "buprenorphine": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "buprenorphine with naloxone": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "co-codamol": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "codeine phosphate": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "diamorphine hydrochloride": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "dihydrocodeine tartrate": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "dihydrocodeine with paracetamol": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "dipipanone hydrochloride with cyclizine": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "hydromorphone hydrochloride": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "meptazinol": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "methadone hydrochloride": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "morphine": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 1
    },
    "oxycodone hydrochloride": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "oxycodone with naloxone": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "paracetamol with buclizine hydrochloride and codeine phosphate": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "pentazocine": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "pethidine hydrochloride": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "remifentanil": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "sufentanil": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "tapentadol": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "tramadol hydrochloride": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "tramadol with dexketoprofen": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "tramadol with paracetamol": {
        "stop": [
            {
                "Opiates": "Use of long-term strong opioids as first line therapy for mild-moderate pain (WHO analgesic ladder not observed). Regular opioids for more than 2 weeks in those with chronic constipation without concurrent use of laxatives (risk of severe constipation). Long-term in those with dementia unless for palliative care or management of chronic pain syndrome (exacerbation of cognitive impairment). Long-term in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). Slow-release opioids in severe pain without short-acting opioids for break-through pain (risk of persistence of severe pain)."
            }
        ],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "isocarboxazid": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "moclobemide": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "phenelzine sulfate": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "tranylcypromine sulfate": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "agomelatine": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "mirtazapine": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 1
    },
    "nefazodone hydrochloride": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "oxitriptan": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "reboxetine": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "tryptophan": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "venlafaxine": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 1
    },
    "vortioxetine": {
        "stop": [],
        "start": [
            {
                "Antidepressant (non TCA)": "In the presence of moderate-severe depressive symptoms lasting at least three months (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs)."
            }
        ],
        "score": 0
    },
    "ropinirole": {
        "stop": [],
        "start": [
            {
                "Dopamine agonist (ropinirole or pramipexole or rotigotine)": "For moderate-severe Restless Legs Syndrome, once iron deficiency and severe renal failure have been excluded and in conjunction with lifestyle measures."
            }
        ],
        "score": 0
    },
    "donepezil hydrochloride": {
        "stop": [],
        "start": [
            {
                "Acetylcholinesterase inhibitor": "For mild-moderate Alzheimer\u2019s dementia or Lewy Body dementia (rivastigmine) following review and recommendation by specialist team. Use donepezil first line. (e.g. donepezil, rivastigmine, galantamine \u2013 or Memantine if others not tolerated)"
            }
        ],
        "score": 0
    },
    "rivastigmine": {
        "stop": [],
        "start": [
            {
                "Acetylcholinesterase inhibitor": "For mild-moderate Alzheimer\u2019s dementia or Lewy Body dementia (rivastigmine) following review and recommendation by specialist team. Use donepezil first line. (e.g. donepezil, rivastigmine, galantamine \u2013 or Memantine if others not tolerated)"
            }
        ],
        "score": 0
    },
    "galantamine": {
        "stop": [],
        "start": [
            {
                "Acetylcholinesterase inhibitor": "For mild-moderate Alzheimer\u2019s dementia or Lewy Body dementia (rivastigmine) following review and recommendation by specialist team. Use donepezil first line. (e.g. donepezil, rivastigmine, galantamine \u2013 or Memantine if others not tolerated)"
            }
        ],
        "score": 0
    },
    "memantine": {
        "stop": [],
        "start": [
            {
                "Acetylcholinesterase inhibitor": "For mild-moderate Alzheimer\u2019s dementia or Lewy Body dementia (rivastigmine) following review and recommendation by specialist team. Use donepezil first line. (e.g. donepezil, rivastigmine, galantamine \u2013 or Memantine if others not tolerated)"
            }
        ],
        "score": 0
    },
    "\"": {
        "stop": [],
        "start": [
            {
                "Strong opioids ": "In moderate-severe pain, where paracetamol, NSAIDs or weak opioids are not appropriate to the pain severity or have been ineffective. Use morphine first line."
            }
        ],
        "score": 0
    },
    "glibenclamide": {
        "stop": [
            {
                "Sulfonylureas with a long duration of action": "With a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) with type 2 diabetes mellitus (risk of prolonged hypoglycaemia)."
            }
        ],
        "start": [],
        "score": 0
    },
    "chlorpropamide": {
        "stop": [
            {
                "Sulfonylureas with a long duration of action": "With a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) with type 2 diabetes mellitus (risk of prolonged hypoglycaemia)."
            }
        ],
        "start": [],
        "score": 0
    },
    "glimepiride": {
        "stop": [
            {
                "Sulfonylureas with a long duration of action": "With a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) with type 2 diabetes mellitus (risk of prolonged hypoglycaemia)."
            }
        ],
        "start": [],
        "score": 0
    },
    "metformin": {
        "stop": [
            {
                "Metformin": "If eGFR below 30 ml/min/1.73m2 (risk of lactic acidosis)."
            }
        ],
        "start": [],
        "score": 1
    },
    "pioglitazone": {
        "stop": [
            {
                "Pioglitazone": "In patients with heart failure (risk of exacerbation of heart failure)."
            }
        ],
        "start": [],
        "score": 0
    },
    "diethylstilbestrol": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estradiol": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            },
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estradiol acetate": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estradiol and estriol with progestogen": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estriol and estrone": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estradiol valerate": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estradiol with progestogen": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estriol": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "estropipate": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "ethinylestradiol": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "oestrogens conjugated": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "oestrogens conjugated with bazedoxifene": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "oestrogens conjugated with progestogen": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "raloxifene hydrochloride": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "tibolone": {
        "stop": [
            {
                "Oestrogens": "With a history of breast cancer or venous thromboembolism (increased risk of recurrence). Without progestogen in patients with intact uterus (risk of endometrial cancer)."
            },
            {
                "Any hormone replacement therapy in females": "With:  Acute liver disease (metabolised by the liver). Oestrogen-dependent cancer (may worsen prognosis). Undiagnosed vaginal bleeding or untreated endometrial hyperplasia . Active thrombophlebitis, thrombophilic disorder (increased risk of venous thromboembolism). Active or recent arterial thromboembolic disease (e.g. angina or myocardial Infarction) (at increased risk of arterial thrombosis)."
            }
        ],
        "start": [
            {
                "Topical vaginal oestrogen or vaginal oestrogen pessary ": "For symptomatic atrophic vaginitis."
            }
        ],
        "score": 0
    },
    "testosterone": {
        "stop": [
            {
                "Androgens (male sex hormones)": "In the absence of primary or secondary hypogonadism (risk of androgen toxicity; no proven benefit outside of the hypogonadism indication)."
            }
        ],
        "start": [],
        "score": 0
    },
    "testosterone enantate": {
        "stop": [
            {
                "Androgens (male sex hormones)": "In the absence of primary or secondary hypogonadism (risk of androgen toxicity; no proven benefit outside of the hypogonadism indication)."
            }
        ],
        "start": [],
        "score": 0
    },
    "testosterone esters": {
        "stop": [
            {
                "Androgens (male sex hormones)": "In the absence of primary or secondary hypogonadism (risk of androgen toxicity; no proven benefit outside of the hypogonadism indication)."
            }
        ],
        "start": [],
        "score": 0
    },
    "testosterone propionate": {
        "stop": [
            {
                "Androgens (male sex hormones)": "In the absence of primary or secondary hypogonadism (risk of androgen toxicity; no proven benefit outside of the hypogonadism indication)."
            }
        ],
        "start": [],
        "score": 0
    },
    "testosterone undecanoate": {
        "stop": [
            {
                "Androgens (male sex hormones)": "In the absence of primary or secondary hypogonadism (risk of androgen toxicity; no proven benefit outside of the hypogonadism indication)."
            }
        ],
        "start": [],
        "score": 0
    },
    "alendronic acid with colecalciferol": {
        "stop": [
            {
                "Bisphosphonates": "If greater than 5 years treatment duration (for drug holiday), after discussion of risks and benefits.\nIf unexplained thigh, hip or groin pain is reported, after discussion of risks and benefits. Given orally in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
            }
        ],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            }
        ],
        "score": 0
    },
    "ibandronic acid": {
        "stop": [
            {
                "Bisphosphonates": "If greater than 5 years treatment duration (for drug holiday), after discussion of risks and benefits.\nIf unexplained thigh, hip or groin pain is reported, after discussion of risks and benefits. Given orally in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
            },
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "pamidronate disodium": {
        "stop": [
            {
                "Bisphosphonates": "If greater than 5 years treatment duration (for drug holiday), after discussion of risks and benefits.\nIf unexplained thigh, hip or groin pain is reported, after discussion of risks and benefits. Given orally in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
            },
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "risedronate sodium": {
        "stop": [
            {
                "Bisphosphonates": "If greater than 5 years treatment duration (for drug holiday), after discussion of risks and benefits.\nIf unexplained thigh, hip or groin pain is reported, after discussion of risks and benefits. Given orally in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
            },
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "risedronate with calcium carbonate and colecalciferol": {
        "stop": [
            {
                "Bisphosphonates": "If greater than 5 years treatment duration (for drug holiday), after discussion of risks and benefits.\nIf unexplained thigh, hip or groin pain is reported, after discussion of risks and benefits. Given orally in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
            }
        ],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            }
        ],
        "score": 0
    },
    "sodium clodronate": {
        "stop": [
            {
                "Bisphosphonates": "If greater than 5 years treatment duration (for drug holiday), after discussion of risks and benefits.\nIf unexplained thigh, hip or groin pain is reported, after discussion of risks and benefits. Given orally in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
            },
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "zoledronic acid": {
        "stop": [
            {
                "Bisphosphonates": "If greater than 5 years treatment duration (for drug holiday), after discussion of risks and benefits.\nIf unexplained thigh, hip or groin pain is reported, after discussion of risks and benefits. Given orally in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
            },
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "alendronic acid": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "alendronic acid/colecalciferol": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "denosumab": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            },
            {
                "Denosumab": "If patient is unable to have regular dental check ups."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "etidronate disodium": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "other bisphosphonate and other preparations": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "romosozumab": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "strontium ranelate": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "tiludronic acid": {
        "stop": [
            {
                "Bisphosphonates or Denosumab": "In patients considered at low fracture risk (FRAX \u00ae assessment tool)."
            }
        ],
        "start": [
            {
                "Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate) ": "In patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone Mineral Density T-scores is less than -2.5 in multiple sites) and/or previous history of fragility fracture(s)."
            }
        ],
        "score": 0
    },
    "alfacalcidol": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "calcifediol": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "calcitriol": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "colecalciferol": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "dihydrotachysterol": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "ergocalciferol": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "other vitamin d preparations": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "paricalcitol": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "calcium carbonate": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "calcium chloride": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "calcium gluconate": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "calcium lactate": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "hydroxyapatite": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "other calcium supplement preparations": {
        "stop": [],
        "start": [
            {
                "Bisphosphonates and vitamin D and calcium (where dietary calcium intake inadequate)": "In patients taking long-term systemic glucocorticosteroid therapy (greater than or equal to 7.5 mg prednisolone per day (or equivalent) for 3 months or more)."
            },
            {
                "Vitamin D and calcium (where dietary calcium intake inadequate)": "Supplement: In patients with known osteoporosis and/or previous fragility fracture(s) and/or (Bone Mineral Density T-scores greater than -2.5 in multiple sites). In older people who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is in the range of -1 to -2.5 in multiple sites)."
            }
        ],
        "score": 0
    },
    "alfuzosin hydrochloride": {
        "stop": [
            {
                "Alpha1-receptor blocker": "In those with symptomatic orthostatic hypotension or micturition syncope (risk of precipitating recurrent syncope)."
            }
        ],
        "start": [
            {
                "Alpha1-receptor blocker": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "doxazosin": {
        "stop": [
            {
                "Alpha1-receptor blocker": "In those with symptomatic orthostatic hypotension or micturition syncope (risk of precipitating recurrent syncope)."
            }
        ],
        "start": [
            {
                "Alpha1-receptor blocker": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "indoramin": {
        "stop": [
            {
                "Alpha1-receptor blocker": "In those with symptomatic orthostatic hypotension or micturition syncope (risk of precipitating recurrent syncope)."
            }
        ],
        "start": [
            {
                "Alpha1-receptor blocker": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "prazosin": {
        "stop": [
            {
                "Alpha1-receptor blocker": "In those with symptomatic orthostatic hypotension or micturition syncope (risk of precipitating recurrent syncope)."
            }
        ],
        "start": [
            {
                "Alpha1-receptor blocker": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "tamsulosin with dutasteride": {
        "stop": [
            {
                "Alpha1-receptor blocker": "In those with symptomatic orthostatic hypotension or micturition syncope (risk of precipitating recurrent syncope)."
            }
        ],
        "start": [
            {
                "Alpha1-receptor blocker": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            },
            {
                "5-alpha reductase inhibitor": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "tamsulosin with solifenacin": {
        "stop": [
            {
                "Alpha1-receptor blocker": "In those with symptomatic orthostatic hypotension or micturition syncope (risk of precipitating recurrent syncope)."
            }
        ],
        "start": [
            {
                "Alpha1-receptor blocker": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "terazosin": {
        "stop": [
            {
                "Alpha1-receptor blocker": "In those with symptomatic orthostatic hypotension or micturition syncope (risk of precipitating recurrent syncope)."
            }
        ],
        "start": [
            {
                "Alpha1-receptor blocker": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "sildenafil": {
        "stop": [
            {
                "Phosphodiesterase type-5 inhibitors": "In severe heart failure characterised by hypotension i.e. systolic BP below 90 mmHg, or concurrent nitrate therapy for angina (risk of cardiovascular collapse)."
            }
        ],
        "start": [],
        "score": 0
    },
    "avanafil": {
        "stop": [
            {
                "Phosphodiesterase type-5 inhibitors": "In severe heart failure characterised by hypotension i.e. systolic BP below 90 mmHg, or concurrent nitrate therapy for angina (risk of cardiovascular collapse)."
            }
        ],
        "start": [],
        "score": 0
    },
    "tadalafil": {
        "stop": [
            {
                "Phosphodiesterase type-5 inhibitors": "In severe heart failure characterised by hypotension i.e. systolic BP below 90 mmHg, or concurrent nitrate therapy for angina (risk of cardiovascular collapse)."
            }
        ],
        "start": [],
        "score": 0
    },
    "vardenafil": {
        "stop": [
            {
                "Phosphodiesterase type-5 inhibitors": "In severe heart failure characterised by hypotension i.e. systolic BP below 90 mmHg, or concurrent nitrate therapy for angina (risk of cardiovascular collapse)."
            }
        ],
        "start": [],
        "score": 0
    },
    "amiloride hydrochloride": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "triamterene": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 1
    },
    "amiloride hydrochloride with loop diuretics": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "amiloride hydrochloride with thiazides": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "co-amilofruse (amiloride hydrochloride/frusemide)": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "co-amilozide (amiloride hydrochloride/hydrochlorothiazide)": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "co-flumactone (hydroflumethiazide/spironolactone)": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "co-triamterzide(triamterene/hydrochlorothiazide)": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "spironolactone with loop diuretics": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "spironolactone with thiazides": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "triamterene with loop diuretics": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "triamterene with thiazides": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "mannitol": {
        "stop": [
            {
                "Diuretics": "Diuretics or other drugs that increase urinary flow with concurrent urinary incontinence (may exacerbate incontinence)."
            }
        ],
        "start": [],
        "score": 0
    },
    "finasteride": {
        "stop": [],
        "start": [
            {
                "5-alpha reductase inhibitor": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "dutasteride": {
        "stop": [],
        "start": [
            {
                "5-alpha reductase inhibitor": "With symptomatic prostatism, where prostatectomy is not considered necessary."
            }
        ],
        "score": 0
    },
    "compound iron preparations": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "ferric maltol": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "ferrous calcium citrate": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "ferrous fumarate": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "ferrous gluconate": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "ferrous glycine sulfate": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "ferrous sulfate": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "higher folic acid content": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "iron and folic acid": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "other oral iron preparations": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "polysaccharide-iron complex": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "sodium feredetate": {
        "stop": [
            {
                "Oral elemental iron doses": "Greater than 200 mg daily e.g. ferrous fumarate above 600 mg/day, ferrous sulphate above 600 mg/day, ferrous gluconate above 1800."
            }
        ],
        "start": [],
        "score": 0
    },
    "aceclofenac": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "acemetacin": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "azapropazone": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "benorilate": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "dexketoprofen": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "diclofenac potassium": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "diclofenac sodium": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "diflunisal": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "etodolac": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "fenbufen": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "fenoprofen": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "flurbiprofen": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "ibuprofen lysine": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "ibuprofen sodium dihydrate": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "indometacin": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "ketoprofen": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "lornoxicam": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "lumiracoxib": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "meloxicam": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "nabumetone": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "naproxen sodium": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "phenylbutazone": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "piroxicam": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "rofecoxib": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "sulindac": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "tenoxicam": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "tiaprofenic acid": {
        "stop": [
            {
                "NSAID": "With history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent, appropriate gastroprotection (risk of peptic ulcer relapse). With concurrent oral corticosteroid, antiplatelet (especially Aspirin) or antidepressant (SSRI, Venlafaxine) without concurrent, appropriate gastroprotection (increased risk of peptic ulcer disease). With severe or uncontrolled hypertension (risk of exacerbation of hypertension). With moderate-severe heart failure (risk of exacerbation of heart failure). Do not use Diclofenac or a COX-2 selective agent at any stage of heart failure. Long-term (beyond 3 months) for symptom relief of musculoskeletal pain where simple analgesia and/ or topical NSAID (where appropriate) has not been tried (may be as effective for pain relief). If eGFR less than 50 ml/min/1.73m2 (risk of deterioration in renal function). With warfarin or NOAC (risk of gastrointestinal bleeding)."
            },
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            }
        ],
        "start": [],
        "score": 0
    },
    "colchicine": {
        "stop": [
            {
                "Long-term NSAID or Colchicine": "For chronic treatment of gout where there is no contraindication to Allopurinol (xanthine-oxidase inhibitors are first choice prophylactic drugs in gout)(beyond 3 months)."
            },
            {
                "Colchicine": "If eGFR less than 10 ml/min/1.73m2 (risk of colchicine toxicity)."
            }
        ],
        "start": [],
        "score": 0
    },
    "quinine": {
        "stop": [
            {
                "Quinine": "Take a trial break every three months, unless leg cramps are painful and cause regular disruption of sleep. If no benefit after four weeks."
            }
        ],
        "start": [],
        "score": 0
    },
    "allopurinol": {
        "stop": [],
        "start": [
            {
                "Allopurinol": "With a history of recurrent episodes of gout."
            }
        ],
        "score": 0
    },
    "folic acid": {
        "stop": [],
        "start": [
            {
                "Folic acid": "Supplement in patients taking methotrexate, following local shared care guideline."
            }
        ],
        "score": 0
    },
    "latanoprost": {
        "stop": [],
        "start": [
            {
                "Topical prostaglandin, prostamide or beta-blocker": "For primary open-angle glaucoma."
            }
        ],
        "score": 0
    },
    "travoprost": {
        "stop": [],
        "start": [
            {
                "Topical prostaglandin, prostamide or beta-blocker": "For primary open-angle glaucoma."
            }
        ],
        "score": 0
    },
    "tafluprost": {
        "stop": [],
        "start": [
            {
                "Topical prostaglandin, prostamide or beta-blocker": "For primary open-angle glaucoma."
            }
        ],
        "score": 0
    },
    "prostamide": {
        "stop": [],
        "start": [
            {
                "Topical prostaglandin, prostamide or beta-blocker": "For primary open-angle glaucoma."
            }
        ],
        "score": 0
    },
    "betaxolol": {
        "stop": [],
        "start": [
            {
                "Topical prostaglandin, prostamide or beta-blocker": "For primary open-angle glaucoma."
            }
        ],
        "score": 0
    },
    "levobunolol": {
        "stop": [],
        "start": [
            {
                "Topical prostaglandin, prostamide or beta-blocker": "For primary open-angle glaucoma."
            }
        ],
        "score": 0
    },
    "5-hydroxytryptophan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "abacavir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "abiraterone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acamprosate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acarbose": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acebutolol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acetaminophen": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acetazolamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acetic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acetohexamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acetylcarnitine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acetylcysteine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "aciclovir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acidophilus": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acitretin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "aclinidium": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acyclovir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "acyl carnitine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "adalimumab": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "adefovir dipivoxil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "adenosine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "adrenaline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "al hydroxide/mg hydroxide/simethicone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "albumin human": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "albuterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alclometasone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alendronate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alfuzosin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alginic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "aliskiren": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "aloe vera": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alpha-d-galactosidase": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alprostadil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alteplase": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "aluminum acetate topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "aluminum carbonate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "aluminum hydroxide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alzelaic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "amiloride": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "amino acids": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ammonium lactate topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "amoxicillin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "amoxicillin-clavulanate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "amphetamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "amphotericin b": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "anagrelide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "anakinra": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "anastrozole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "apap/dichloralphenazone/isometheptene": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "apraclonidine ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "apremilast": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "arginine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ascorbic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "atazanavir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "atomoxetine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "attapulgite": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "azathioprine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "azithromycin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bacitracin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "baclofen": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "balsalazide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "balsam peru topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "becaplermin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bee pollen": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "benzocaine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "benzocaine/butamben/tetracaine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "benzonatate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "beta-carotene": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "betahistine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "betaine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "betamethasone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "betamethasone-clotrimazole topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bethanechol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bevacizumab": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bicalutamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bilastine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bilberry": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bimatoprost ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bioflavonoids": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "biotin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bisacodyl": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bismuth subsalicylate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bisoprolol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "black cohosh": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bosentan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "brexpiprazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "brimonidine ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "brinzolamide ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bromazepam": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bromhexine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "bupivacaine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "buspirone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "butabarbital": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "butalbital": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "butenafine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "butoconazole topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "butorphanol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "butylated hydroxytoluene topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cadexomer iodine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "caffeine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "calamine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "calcipotriene topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "calcitonin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "calcium acetate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "calcium-vitamin d": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "camphor topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "camphor-menthol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "canagliflozin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "candesartan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cannabidiol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "capecitabine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "capsaicin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carbachol ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carbamazepine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carbamide peroxide otic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carbimazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carboplatin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carisoprodol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carmellose": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "carnitine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "casanthranol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "casanthranol-docusate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cascara sagrada": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "caspofungin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "castor oil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cat's claw": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cefaclor": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cefadroxil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cefazolin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cefepime": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cefixime": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cefotetan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ceftibuten": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ceftriaxone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cefuroxime": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cephalexin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cerivastatin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cetylpyridinium topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cevimeline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "chamomile": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "charcoal": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "charcoal-sorbitol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "chlorambucil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "chloramphenicol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "chlorhexidine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "chlorzoxazone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cholecalciferol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cholestyramine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "choline salicylate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "chondroitin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "chromium picolinate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ciclopirox topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cilastatin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cilexetil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cilostazol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cinacalcet": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ciprofloxacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cisapride": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cisplatin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "citric acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "clarithromycin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "clavulanate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "clindamycin cream or gel": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "clobetasol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "clodronate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "clofazimine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "clotrimazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cloxacillin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "coal tar topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cod liver oil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "codeine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "coenzyme q10": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "colesevelam": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "colestipol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "colistin sulfate otic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "collagenase topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "conjugated estrogens": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "conjugated estrogens topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cosyntropin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cranberry": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cromolyn": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "curcumin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cyanocobalamin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cyclophosphamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cyclosporin eye drops": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "cyproterone acetate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dalteparin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "danazol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dandelion": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dantrolene": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dapagiflozin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dapsone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "daptomycin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "darbepoetin alfa": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "darunavir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dehydroepiandrosterone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "demeclocycline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "desmopressin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "desonide topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "desoximetasone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dexamethasone nasal": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dexamethasone ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dexamethasone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dexlansoprazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dextroamphetamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dibucaine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "diclofenac-misoprostol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dicloxacillin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "didanosine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dienestrol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dihydroxyaluminum sodium carbonate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dimeticone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "diphenoxylate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dipivefrin ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dirithromycin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "disulfiram": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "divalproex sodium": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dobutamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "docosanol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "docusate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "docusate-senna": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dofetilide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "donepezil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dopamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dorzolamide ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "doxercalciferol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "doxycycline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dronedarone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dulaglutide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "duloxetine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dutaseride": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dydrogesterone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "dyphylline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "echinacea": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "econazole topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "edrophonium": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "efavirenz": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "efinaconazole topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "eflornithine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "eletriptan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "emollients": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "empagliflozin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "emtricitabine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "enalapril": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "enoxaparin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "enriched soy lecithin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ephedrine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "epinastine ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "epinephrine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "epoetin alfa": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ergoloid mesylates": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "erlotinib": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ertapenem": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "erythromycin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "estazolam": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "esterified estrogens": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "estradiol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "eszopiclone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "etanercept": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ethambutol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ethinyl estradiol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "etidronate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "etomidate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "etoposide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "evening primrose": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "evolocumab": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "exemestane": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "exenatide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ezetimibe": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "factor ix complex": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "famciclovir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "febuxostat": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "felbamate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fenofibrate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fexofenadine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "filgrastim": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "flax": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "flecainide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "flucloxacillin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluconazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fludrocortisone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "flumazenil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "flunisolide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "flunizepam": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluocinolone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluocinonide topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluoride": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluoride topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluorometholone ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluorouracil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "flutamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluticasone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluticasone-salmeterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fluvastatin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "formoterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fosinopril": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "fosphenytoin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "framycetin sulphate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gabapentin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ganciclovir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "garlic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gatifloxacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gemfibrozil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gemifloxacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gentamicin ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gentamicin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ginger": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ginkgo": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ginseng": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glatiramer": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gliclazide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glipizide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glucagon": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glucosamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glucose": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glutamic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glyburide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glyceril trinitrate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glycerin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "glycine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "goserelin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gotu kola": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "gramicidin ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "grape seed oil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "green tea": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "griseofulvin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "guanabenz": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "guanfacine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "halcinonide topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "halobetasol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hawthorn": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "heme iron polypeptide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "heparin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hetastarch": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hexachlorophene topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "holy basil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "horse chestnut": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "huperzine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydrocodone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydrocortisone ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydrocortisone otic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydrocortisone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydrogen peroxide topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydromorphone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydroxychloroquine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydroxypropyl methylcellulose ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydroxyquinoline topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hydroxyurea": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "hypromellose": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ibandronate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "imatinib": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "imipenem": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "imipenem-cilastatin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "imiquimod topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "immune globulin intramuscular": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "immune globulin intravenous": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "immune globulin subcutaneous": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "indacaterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "infliximab": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "influenza virus vaccine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "inosine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "inositol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "insulin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "interferon beta-1a": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "interferon beta-1b": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "inuflora": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "irinotecan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "iron polysaccharide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "isoniazid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "isopropyl alcohol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "isotretinoin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "itraconazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "kaolin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ketoconazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ketoralac": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ketorolac ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "l-histadine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "l-theanine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "l-tyrosine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "labetalol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lactase": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lactic acid topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lactobacillus acidophilus": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lactulose": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lamivudine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lamotrigine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lanolin-mineral oil topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lanthanum carbonate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "latanoprost ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lecithin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "leflunomide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lercanidipine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "letrozole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "leucovorin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "leuprolide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "levalbuterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "levetiracetam": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "levmetamfetamine nasal": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "levobunolol ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "levocarnitine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "levofloxacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "levothyroxine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "licorice": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lidocaine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "linaclotide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "linagliptin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lindane topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "linezolid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "liothyronine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "liotrix": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lipoic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "liraglutide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lodoxamide ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "loracarbef": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "losartan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "loteprednol ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lubiprostone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lutein": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lvp solution": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lycopene": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "lysine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium amino acids chelate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium carbonate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium chloride": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium citrate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium gluconate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium glycinate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium hydroxide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium oxide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium salicylate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium sulfate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "magnesium trisilicate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "manganese": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mebeverine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "medroxyprogesterone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mefloquine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "megestrol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "melphalan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "menthol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "meperidine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "meprobamate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mequinol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mercaptopurine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "meropenem": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mesalazine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mestranol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "metaproterenol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "metaxalone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methazolamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methenamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methenamine-sodium biphosphate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methimazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methotrexate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methyclothiazide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methyl salicylate topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methylene blue": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methylphenidate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methylprednisolone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methylsulfonylmethane": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "methyltestostone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "metipranolol ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "metoprolol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "metronidazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mexiletine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mianserin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "miconazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "midodrine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "miglitol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "milk thistle": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mineral oil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "minocycline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "minoxidil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mirabegron": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "misoprostol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "modafinil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "moexipril": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "molindone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mometasone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "montelukast": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "moricizine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "moxifloxacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "multivitamin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mupirocin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mycophenolate mofetil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "mycophenolic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "n-acetyl-tyrosine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nabilone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "naloxone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "naltrexone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "naphazoline ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nateglinide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nefazodone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "neomycin ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "neomycin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "neostigmine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nettles": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nevirapine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "niacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nicardipine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nicotinamide riboside": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nicotine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nitrofurantoin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nitroglycerin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nitroprusside": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "norepinephrine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "norethisterone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "norfloxacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "nystatin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "octreotide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ocular lubricant": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ofloxacin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "olmesartan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "olodaterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "omega-3 polyunsaturated fatty acids": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "omega-3-ethyl esters": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ondansetron": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "orlistat": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "orthosilicic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "oseltamivir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "oxaprozin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "oxcarbazepine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "oxiconazole topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "oxymetazoline nasal": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pamabrom": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pamidronate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pancrelipase": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "papain-urea topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "papaverine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "papaya": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "paracetamol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pectin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "penicillin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pentoxifylline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pergolide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "perindopril": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "permethrin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "petrolatum topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phenazopyridine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phenol topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phenolphthalein": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phentermine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phentolamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phenyl salicylate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phenylephrine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phenylpropanolamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phenytoin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phosphatidyl serine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phosphorated carbohydrate solution": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "phytonadione": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pilocarpine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pimecrolimus topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pirbuterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pivampicillin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "podophyllum": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "polycarbophil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "polyethylene glycol 3350": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "polyethylene glycol 3350 with electrolytes": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "polymyxin b ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "polymyxin b topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium acetate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium bicarbonate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium bicarbonate-potassium citrate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium chloride": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium citrate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium gluconate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium iodide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium phosphate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "potassium phosphate-sodium phosphate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pramlintide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pramoxine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pramoxine-zinc oxide topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "prednisolone eye drops": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pregabalin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pregnenolone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "prilocaine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "primidone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "probenecid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "probiotic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "progesterone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "propafenone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "propofol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "propoxyphene": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "propranolol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "propylene glycol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "propylthiouracil": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "protamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pseudoephedrine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "psyllium": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pycnogenol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pygeum": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pyrazinamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pyridostigmine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "pyridoxine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "quinapril": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "quinine phenylethylbarbiturate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rabeprazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "raloxifene": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ramelteon": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rasagiline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "red yeast rice": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "repaglinide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "reserpine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "resveratrol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rhodiola rosea": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ribavirin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rifampin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rilpivirine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rimantadine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rimexolone ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "risedronate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ritonavir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rizatriptan": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "rosiglitazone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "roxythromycin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "royal jelly": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "s-adenosylmethionine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "salbutamol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "salicylamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "salicylic acid topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "salmeterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "salsalate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sargramostim": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sarilumab": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "saw palmetto": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "saxagliptin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "selenium": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "senna": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sevelamer": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "shark cartilage": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sibutramine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "silodosin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "silver sulfadiazine topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "simethicone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sirolimus": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sitagliptin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium bicarbonate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium biphosphate-sodium phosphate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium chloride": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium chloride nasal": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium chloride, hypertonic, ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium citrate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium ferric gluconate complex": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium hyaluronate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium phosphate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium picosulfate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sodium polystyrene sulfonate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sofosbuvir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sorbitol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sotalol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "st. john's wort": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "stavudine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "strontium": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "succinylcholine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sucralfate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfacetamide sodium ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfacetamide sodium topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfadiazine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfamethizole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfamethoxazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfamethoxazole-trimethoprim": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfasalazine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "sulfur topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tacrine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tacrolimus": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tamoxifen": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tamsulosin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "taurine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tazarotene topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tazobactam": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tegaserod": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "telithromycin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "temozolomide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tenofovir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "terbinafine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "terbutaline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "terconazole topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "teriparatide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tetanus-diphtheria toxoids": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tetracycline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tetrahydrozoline ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "thalidomide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "thiamazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "thiamine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "thiothixene": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "thonzonium bromide otic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "thyrotropin alpha": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "thyroxine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ticarcillin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ticlopidine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tizanidine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tobramycin ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tofacitinib": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tolazamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tolbutamide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tolmetin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "topiramate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "torsemide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tranexamic acid": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "travoprost ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "trazodone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tretinoin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "triamcinolone nasal": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "triamcinolone topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tribulus terrestris": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "trichlormethiazide": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "triethanolamine polypeptide oleate otic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "trifluperidol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "trimethoprim": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "troglitazone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "trolamine salicylate topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tropisetron": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "trypsin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "trypsin topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "tuberculin purified protein derivative": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "turmeric": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ubiquinone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "unoprostone ophthalmic": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "urea topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "ursodiol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "valacyclovir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "valdecoxib": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "valerian": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "varenicline": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vasopressin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vecuronium": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "velpatasvir": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vemurafenib": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vigabatrin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vilanterol": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vilazodone": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vincristine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vinpocetine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vitamin a": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vitamin a & d topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "vitamin e": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "voriconazole": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "wheat dextrin": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "wild yam": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "witch hazel topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "yohimbine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "zafirlukast": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "zidovudine": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "zileuton": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "zinc citrate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "zinc gluconate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "zinc oxide topical": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "zinc sulfate": {
        "stop": [],
        "start": [],
        "score": 0
    },
    "alimemazine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "alverine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "amantadine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "aminophylline": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ampicillin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "asenapine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "azelastine nasal": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "azelastine ophthalmic": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "barberry": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "bromocriptine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "bupropion": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "carbidopa-levodopa": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cefamandole": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cefoxitin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cephalothin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cetirizine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "chlordiazepoxide": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "chloroquine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ciclosporin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cimetidine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "clindamycin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "clonazepam": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "clorazepate": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "corticosterone": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cortisone": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cycloserine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "cyclosporine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "desloratadine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "desvenlafaxine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "dextromethorphan": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "digitoxin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "dimetindene": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "diphenhydramine cream": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ergotamine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "fentanyl": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "fentanyl topical": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "flunitrazepam": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "fluoxetine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "fluphenazine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "flurazepam": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "fluvoxamine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "gentamicin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "glycopyrronium - inhaled": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "guaifenesin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "hydralazine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "hydroxyzine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "iloperidone": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ipratropium": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ipratropium nasal": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "isosorbide": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "isosorbide dinitrate": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "isosorbide mononitrate": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ketotifen ophthalmic": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "levocetirizine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "lithium": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "loperamide": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "loratadine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "meclizine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "methadone": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "midazolam": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "nalbuphine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "naratriptan": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "neomycin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "nizatidine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "olopatadine ophthalmic": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "oxycodone": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "pancuronium": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "phenelzine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "pheniramine ophthalmic": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "phenobarbitol": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "piperacillin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "procainamide": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "quinidine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ranitidine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "selegiline": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "sertraline": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "sumatriptan": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "temazepam.": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "tiagabine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "tiotropium": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "tobramycin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "tranylcypromine": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "triazolam": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "umeclidinium": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "valproic acid": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "vancomycin": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "ziprasidone": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "zolmitriptan": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "zuclopenthixol": {
        "stop": [],
        "start": [],
        "score": 1
    },
    "disopyramide": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "homatropine ophthalmic": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "loxapine": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "maprotiline": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "mesoridazine": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "methotrimeprazine": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "nefopam": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "opipramol": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "pethidine": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "tramadol": {
        "stop": [],
        "start": [],
        "score": 2
    },
    "amitriptyline": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "atropine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "azatadine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "belladonna": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "benztropine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "biperiden": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "brompheniramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "buclizine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "carbinoxamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "chlorpromazine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "clemastine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "clidinium": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "clomipramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "cyclobenzaprine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "cyproheptadine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "darifenacin": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "desipramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "dexbrompheniramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "dexchlorpheniramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "dicycloverine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "dimenhydrinate": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "diphenhydramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "dosulepin": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "doxylamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "fesoterodine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "flavoxate": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "glycopyrronium injectable": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "homatropine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "hyoscine butylbromide": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "hyoscine hydrobromide": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "hyoscyamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "imipramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "ketamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "methocarbamol": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "methscopolamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "orphenadrine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "oxybutynin": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "paroxetine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "phenindamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "pheniramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "phenyltoloxamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "procyclidine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "propantheline": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "propiverine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "protriptyline": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "pyrilamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "scopolamine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "scopolamine topical": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "solifenacin": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "tolterodine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "triflupromazine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "trihexyphenidyl": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "trimethobenzamide": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "trimipramine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "triprolidine": {
        "stop": [],
        "start": [],
        "score": 3
    },
    "trospium": {
        "stop": [],
        "start": [],
        "score": 3
    }
}